Shanchol

5 Year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial

Article published in The Lancet on 17-Oct-2013 by Bhattacharya, S. K. et al.

BACKGROUND:

Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India.

First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012

Article published in PLoS Neglected Tropical Diseases on 17-Oct-2013 by Luquero, F. J. et al.

BACKGROUND: Despite World Health Organization (WHO) prequalification of two safe and effective oral cholera vaccines (OCV), concerns about the acceptability, potential diversion of resources, cost and feasibility of implementing timely campaigns has discouraged their use. In 2012, the Ministry of Health of Guinea, with the support of Medecins Sans Frontieres organized the first mass vaccination campaign using a two-dose OCV (Shanchol) as an additional control measure to respond to the on-going nationwide epidemic. Overall, 316,250 vaccines were delivered. Here, we present the results of vaccination coverage, acceptability and surveillance of adverse events.

Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea

Article published in PLoS Medicine on 10-Sep-2013 by Ciglenecki, I. et al.

Iza Ciglenecki and colleagues from Medecins sans Frontieres report their experience of undertaking a mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. The authors provide the following summary points: